Syndax Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by Syndax Pharmaceuticals, Inc. on June 10, 2019. The company is an emerging growth company incorporated in Delaware.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes
No material financial changes or operational updates are disclosed in this filing. The document details the ratification of the independent auditor and the election of directors.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future financial performance or risks. It strictly reports the voting results for two proposals submitted to stockholders.
Key Investor Verification Points
- Director Election: All three nominees (Keith A. Katkin, Briggs W. Morrison, M.D., and Dennis G. Podlesak) were elected to three-year terms.
- Auditor Ratification: Stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
- Voting Support: Proposal 1 received significant support, though Keith A. Katkin had a higher number of withheld votes compared to the other nominees. Proposal 2 received overwhelming support with minimal votes against.
- Broker Non-Votes: There were 3,499,438 broker non-votes recorded for the director election proposal.